Quotient Clinical acquires second GMP manufacturing facility

Quotient Clinical, the Translational Pharmaceutics Company, has announced a significant expansion of its pharmaceutical sciences capabilities, doubling capacity through the acquisition of a second GMP manufacturing facility and the construction of new formulation development and pharmaceutical analysis laboratories.

The new laboratories, based within the company’s existing Nottingham facility, were commissioned in response to an increasing customer demand for Quotient’s formulation development services, and have a footprint of approximately 8,000 square feet. The new GMP manufacturing facility is located in the MediCity innovation hub in Nottingham, and has a footprint of 3,000 square feet. It comprises eight multipurpose suites, offering the opportunity to manufacture drug products on a large scale, with all the necessary containment controls to enable safe handling of high potency molecules. The facility is scheduled to become operational later in 2015 following an MHRA inspection.

Real-time GMP manufacturing reduces development timelines and associated costs

Mark Egerton, CEO Quotient Clinical, said, “This expansion is in direct response to the increasing demand for our Translational Pharmaceutics services. Our approach of integrating formulation development, real-time GMP manufacturing and clinical testing is proving an attractive option to reduce development timelines and associated costs.”

Nikki Whitfield, Vice President, Pharmaceutical Sciences, Quotient Clinical, added, “These new facilities form a key component of our strategy to expand our pharmaceutical sciences capacity and capabilities. We will continue to focus on building advanced formulation development approaches to solve important challenges in drug development, and our expanded GMP manufacturing capacity will allow us to support Translational Pharmaceutics programs at Quotient, or to supply drug products to other clinical centres of excellence worldwide.”